Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | NR1H3 | Q13133 | 9/20 | 0.54 |
| ▸ | NR1H2 | P55055 | 8/20 | 0.54 |
| ▸ | MLYCD | O95822 | 7/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19281534 | 0.87 | NR1H3 (0.51) | NR1H3NR1H2 | |
| SCHEMBL1814770 | 0.87 | NR1H3 (0.51) | NR1H3NR1H2 | |
| SCHEMBL2497436 | 0.84 | EPHX2 (0.44) | LMNAHTT | |
| SCHEMBL19150639 | 0.83 | RORC (0.54) | — | |
| SCHEMBL2257964 | 0.83 | NR1H2 (0.55) | SMN1; SMN2NR1H3NR1H2MLYCD | |
| SCHEMBL1812150 | 0.81 | NR1H2 (0.44) | SMN1; SMN2NR1H3NR1H2MLYCD | |
| SCHEMBL1810316 | 0.77 | HSD11B1 (0.40) | SMN1; SMN2NR1H3NR1H2MLYCD | |
| SCHEMBL5480662 | 0.77 | RECQL (0.41) | SMN1; SMN2LMNAHTT | |
| SCHEMBL1816434 | 0.77 | PGR (0.40) | SMN1; SMN2NR1H3NR1H2MLYCDLMNA | |
| SCHEMBL1530165 | 0.74 | ESR1 (0.39) | LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110201603-A1 | Novel Acylaminobenzamide Derivatives | BAYER CROPSCIENCE AG (DE) | 2011-08-18 | — | — | US | disclosed |
| EP-2318358-A2 | ACYLAMINOBENZAMIDE DERIVATIVES | Bayer CropScience AG (DE) | 2011-05-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201603-A1 | Novel Acylaminobenzamide Derivatives | KCNB1, KCNA5, KCNA7 | SMN1; SMN2 4532/4885NR1H3 2856/4885NR1H2 3059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.